keyword
MENU ▼
Read by QxMD icon Read
search

Intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/29785081/pressurized-intraperitoneal-aerosol-chemotheprapy-after-misdiagnosed-gastric-cancer-case-report-and-review-of-the-literature
#1
Maciej Nowacki, Dariusz Grzanka, Wojciech Zegarski
We report the first application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a rescue therapy before palliative D2 gastrectomy combined with liver metastasectomy performed in a 49-year-old woman with peritoneal carcinomatosis who was primarily diagnosed with and underwent surgery for a Krukenberg tumor. The PIPAC procedure was performed with the use of cisplatin at 7.5 mg/m2 and doxorubicin at 1.5 mg/m2 for 30 min at 37 °C. Eight weeks after the PIPAC procedure, the patient underwent open classic D2 gastrectomy with the creation of a Roux-en-Y anastomosis (RNY) combined with liver metastasectomy...
May 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29782365/utilization-of-an-alternative-docetaxel-based-intraperitoneal-chemotherapy-regimen-in-patients-with-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-a-continued-need-for-ovarian-cancer-patients
#2
David A Becker, Charles A Leath, Christen L Walters-Haygood, Brentley Q Smith, Kerri S Bevis
OBJECTIVE: The objective of this study was to report the tolerability and toxicity of a regimen consisting of intravenous (IV) docetaxel and intraperitoneal (IP) cisplatin and paclitaxel with granulocyte colony-stimulating factor support. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients with surgical stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma treated with an outpatient IP chemotherapy regimen consisting of docetaxel 75 mg/m IV and cisplatin 75 mg/m IP day 1 followed by paclitaxel 60 mg/m IP day 8 every 21 days...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29782364/the-utility-of-diagnostic-laparoscopy-in-patients-being-evaluated-for-cytoreductive-surgery-and-hyperthermic-peritoneal-chemotherapy
#3
Raquel Bravo, Mehnareh D Jafari, Alessio Pigazzi
BACKGROUND: To assess the role of diagnostic laparoscopy (DL) to evaluate candidates for optimal cytoreduction surgery of peritoneal carcinomatosis (PC) combined with hyperthermic intraperitoneal chemotherapy in a consecutive series. METHODS: The characteristics of 31 patients undergoing DL between August 2012 and October 2016 for a diagnosis of PC secondary to digestive neoplasms were retrospectively reviewed. RESULTS: Laparoscopic evaluation was successful and well-tolerated in 100% patients (N=31)...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29781509/comparative-analgesic-efficacy-of-pregabalin-administered-according-to-either-a-prevention-protocol-or-an-intervention-protocol-in-rats-with-cisplatin-induced-peripheral-neuropathy
#4
F Y Han, A Kuo, J R Nicholson, L Corradinni, M T Smith
Chemotherapy-induced peripheral neuropathy (CIPN) is a type of peripheral neuropathic pain that may be dose-limiting in patients administered potentially curative cancer chemotherapy dosing regimens. In cancer survivors, persistent CIPN adversely affects patient quality of life and so adjuvant drugs (anticonvulsants e.g. pregabalin or antidepressants e.g. amitriptyline) are recommended for the relief of CIPN. However, most studies in rodent models of CIPN involve administration of single bolus doses of adjuvant drugs to assess pain-relieving efficacy...
May 21, 2018: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29779119/a-chemosensitizer-drug-disulfiram-prevents-doxorubicin-induced-cardiac-dysfunction-and-oxidative-stress-in-rats
#5
Varsha K Sonawane, Umesh B Mahajan, Sachin D Shinde, Subhajit Chatterjee, Sandip S Chaudhari, Harshada A Bhangale, Shreesh Ojha, Sameer N Goyal, Chanakya N Kundu, Chandragouda R Patil
In the present study, the preventive effects of orally administered disulfiram (DS) against the doxorubicin (DOX)-induced cardiotoxicity were investigated in rats. DS was orally administered for 7 days at doses of 2, 10, and 50 mg/kg/day. DOX (30 mg/kg) was intraperitoneally administered on the 5th day of the initiation of DS treatment. Within 48 h of injection, DOX treatment significantly altered ECG, elevated the ST height, and increased the QT and QRS intervals. It reduced the cardiac levels of injury markers like creatine kinase isoenzyme-MB and lactate dehydrogenase...
May 10, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29777795/sirna-in-ovarian-cancer-delivery-strategies-and-targets-for-therapy
#6
REVIEW
Dirk van den Brand, Vicky Mertens, Leon F A G Massuger, Roland Brock
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, and the sixth leading cause of cancer related death in women overall. Despite improved surgical techniques and advances in chemotherapy, mortality hardly decreased over the last twenty years. The major problem is that (micro)metastases persevere in the abdominal cavity, causing incurable tumor recurrence. Therefore, there is an imminent need for new therapeutic strategies. Oligonucleotide (ON) based therapies such as RNA interference (RNAi) provide the possibility to specifically address disease-related pathways...
May 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29774943/-progress-in-prophylatic-hyperthermic-intraperitoneal-chemotherapy-for-advanced-gastric-carcinoma
#7
Xinhua Chen, Jun Luo, Hao Liu, Yuehong Chen, Yanfeng Hu, Tuanjie Li, Tian Lin, Yu Zhu, Mingli Zhao, Hao Chen, Guoxin Li, Jiang Yu
Advanced gastric cancer (AGC) has a high recurrence rate (especially peritoneal relapse) and a poor prognosis. Systematic chemotherapy or targeted therapy have not been able to significantly reduce the major cause of an unfavorable prognosis, namely the high peritoneal AGC recurrence rate post-surgery. Further studies concerning the application of hyperthermic intraperitoneal chemotherapy (HIPEC) post curative surgery for AGC patients, namely the prophylactic HIPEC (P-HIPEC), have involved a prophylactic approach to prevent peritoneal relapse following curative gastrectomy in high-risk patients...
May 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29771808/predicting-survival-after-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-appendix-adenocarcinoma
#8
Omer Aziz, Ihab Jaradat, Bipasha Chakrabarty, Chelliah R Selvasekar, Paul E Fulford, Mark P Saunders, Andrew G Renehan, Malcolm S Wilson, Sarah T O'Dwyer
BACKGROUND: Appendix adenocarcinomas are rare tumors with propensity for peritoneal metastasis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is an established treatment with curative intent, but, to date, studies reporting survival have been heterogeneous with regard to their patient groups (including other tumor types), interventions (not all patients receiving intraperitoneal chemotherapy), and follow-up (varying surveillance protocols). OBJECTIVE: The aim of this study is to quantify the impact of this intervention on survival in a homogeneous group of patients with appendix adenocarcinoma receiving standardized treatment and follow-up, and to determine the impact of prognostic indicators on survival...
May 15, 2018: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/29770622/hyperthermic-intraperitoneal-chemotherapy-in-advanced-ovarian-cancer
#9
Tao Wu, Xi Xia Zhao, Guo Qing Wang
No abstract text is available yet for this article.
March 9, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29764445/current-practices-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-peritoneal-surface-malignancies-an-international-survey-of-oncologic-surgeons
#10
Heon Jong Yoo, Jenny J Hong, Young Bok Ko, Mina Lee, Youjin Kim, Hye Young Han, Yong Jung Song, Myong Cheol Lim, Sang-Yoon Park
BACKGROUND: The goal of the study was to investigate the current clinical practices among oncologic surgeons regarding cytoreductive surgery (CRS) with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: From September to October 2016, an online questionnaire surveyed the oncologic surgeons by email. The questionnaire included 20 multiple-choice questions of the following: eligibility for the CRS with HIPEC procedure, perioperative staging and surgery skill, assessment of residual tumors, and method used for intraperitoneal HIPEC...
May 15, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29761503/evaluation-of-the-peritoneal-surface-disease-severity-score-psdss-in-ovarian-cancer-patients-undergoing-cytoreductive-surgery-and-hipec-two-pathogenetic-types-based-study
#11
Roman Yarema, Taras Fetsych, Natalya Volodko, Myron Оhorchak, Orest Petronchak, Roman Huley, Yuriy Mylyan, Olivier Glehen
BACKGROUND AND OBJECTIVES: Clinical experience suggests that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) play an important role in the management of ovarian cancer. In order to improve patient selection, the peritoneal surface disease severity score (PSDSS) was previously introduced for use in colorectal cancer patients. However, almost no data exist regarding the utility of the PSDSS index in ovarian cancer patients. METHODS: A retrospective study of the effectiveness of CRS and HIPEC was carried out in 59 patients with ovarian cancer...
May 14, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29755773/early-experience-with-cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy-at-a-newly-developed-center-for-peritoneal-malignancy
#12
Whitney L Guerrero, Gitonga Munene, Paxton V Dickson, Dina Darby, Andrew M Davidoff, Michael G Martin, Evan S Glazer, David Shibata, Jeremiah L Deneve
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program. Methods: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/HIPEC with clinicopathologic data described. Results: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11-73 years)...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29755762/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-ovarian-and-gastrointestinal-peritoneal-carcinomatosis-results-from-a-7-year-experience
#13
Giulia Montori, Federico Coccolini, Paola Fugazzola, Marco Ceresoli, Matteo Tomasoni, Carolina Rubicondo, Stefano Raimondo, Domenico Pinelli, Michele Colledan, Luigi Frigerio, Luca Ansaloni
Background: An increasing promising evidence and increasing long-term oncologic outcomes support the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as locoregional treatment for peritoneal carcinosis (PC) especially from ovarian and gastrointestinal tumors, but also for others cancers. Methods: A prospective monocentric study was performed in Papa Giovanni XXIII Hospital, Bergamo (Italy). Patients and tumor characteristics were analyzed...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29755682/evaluation-of-the-impact-of-s-adenosylmethionine-dependent-methyltransferase-inhibitor-3-deazaneplanocin-a-on-tissue-injury-and-cognitive-function-in-mice
#14
Eva Lhuissier, Juliette Aury-Landas, Valentine Bouet, Céline Bazille, Yohann Repesse, Thomas Freret, Karim Boumédiene, Catherine Baugé
Cancer patients display cognitive impairment due, at least partly, to the treatments. Additionally, chemotherapeutic treatments can lead to organ injury, limiting their use, and are likely to have negative impacts on patients' quality of life. The aim of this study was to investigate the toxicity of 3-Deazaneplanocin A (DZNep) on several tissues and organs, as well as on cognitive functions. DZNep is an inhibitor of S-adenosylmethionine-dependent methyltransferase (in particular of the histone methyltransferase EZH2) which showed antitumoral functions in preclinical trials but whose effects on behavior and on organs (side effects) are not known...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29753612/concentrations-of-cisplatin-and-doxorubicin-in-ascites-and-peritoneal-tumor-nodules-before-and-after-pressurized-intraperitoneal-aerosol-chemotherapy-pipac-in-patients-with-peritoneal-metastasis
#15
Clemens B Tempfer, Ziad Hilal, Askin Dogan, Miriam Petersen, Günther A Rezniczek
INTRODUCTION: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new means of delivering chemotherapy into the abdomen of patients with peritoneal carcinomatosis (PC). The amount of drug uptake in ascites and peritoneum after PIPAC is unknown. METHODS: Retrospective cohort study of women with PC from gynecological tumors comparing the concentrations of cisplatin and doxorubicin in ascites and peritoneum before and after PIPAC. Concentrations were measured using gas chromatography...
May 4, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29752854/perioperative-factors-associated-with-persistent-opioid-use-after-extensive-abdominal-surgery-in-children-and-adolescents-a-retrospective-cohort-study
#16
Pascal Owusu-Agyemang, Juan P Cata, Antoinette Van Meter, Ravish Kapoor, Acsa M Zavala, Uduak U Williams, January Tsai, Elizabeth Rebello, Lei Feng, Andrea Hayes-Jordan
BACKGROUND: In adults, preoperative opioid use and higher perioperative opioid consumption have been associated with higher odds of persistent opioid use after surgery. There are limited data on the prevalence and factors associated with persistent opioid use after major oncologic surgery in children. AIMS: In this study, we sought to determine the prevalence and factors associated with the development of persistent opioid use in a group of children and adolescents who had undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy...
May 12, 2018: Paediatric Anaesthesia
https://www.readbyqxmd.com/read/29746229/phase-iii-trial-comparing-intraperitoneal-and-intravenous-paclitaxel-plus-s-1-versus-cisplatin-plus-s-1-in-patients-with-gastric-cancer-with-peritoneal-metastasis-phoenix-gc-trial
#17
Hironori Ishigami, Yoshiyuki Fujiwara, Ryoji Fukushima, Atsushi Nashimoto, Hiroshi Yabusaki, Motohiro Imano, Haruhiko Imamoto, Yasuhiro Kodera, Yoshikazu Uenosono, Kenji Amagai, Shigenori Kadowaki, Hiroto Miwa, Hironori Yamaguchi, Takuhiro Yamaguchi, Tempei Miyaji, Joji Kitayama
Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis...
May 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29745097/quality-of-life-after-cytoreductive-surgery-and-hipec-a-single-centre-prospective-study
#18
Nikolaos Kopanakis, Eleftherios-Orestis Argyriou, Dimitra Vassiliadou, Christina Sidera, Maria Chionis, John Kyriazanos, Elias Efstathiou, John Spiliotis
PURPOSE: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has become a crucial method in the management of peritoneal metastasis. This study evaluated the Quality of Life (QoL) post CRS plus HIPEC. METHODS: 80/95 patients underwent CRS plus HIPEC at the Metaxa Cancer Hospital, Piraeus, Greece from 06/2011 to 06/2015 and completed the colorectal version of the Functional Assessment of Cancer Therapy questionnaire (FACTC, version 4) at 1 week pre-operatively and at 1, 3, 6, 12, 18, 24 months post-operatively...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29745096/cytoreduction-and-hipec-for-peritoneal-carcinomatosis-of-pancreatic-cancer
#19
Antonios-Apostolos Tentes, Nicolaos Pallas, Christina Karamveri, Dimitrios Kyziridis, Christos Hristakis
PURPOSE: Peritoneal carcinomatosis of pancreatic cancer is generally considered for palliative treatment. The purpose of this study was to report the outcome of cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in patients with pancreatic cancer and peritoneal carcinomatosis. METHODS: Patients with documented resectable peritoneal carcinomatosis of pancreatic cancer underwent cytoreductive surgery in combination with HIPEC from 2008-2016 by the same surgical team...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29743140/a-phase-i-single-arm-open-label-dose-escalation-study-of-intraperitoneal-cisplatin-and-doxorubicin-in-patients-with-recurrent-ovarian-cancer-and-peritoneal-carcinomatosis
#20
Clemens B Tempfer, Urs Giger-Pabst, Veronika Seebacher, Miriam Petersen, Askin Dogan, Günther A Rezniczek
OBJECTIVE: We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS: We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2 , cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis...
May 6, 2018: Gynecologic Oncology
keyword
keyword
63283
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"